Protalix Q3 2023 Earnings Report
Key Takeaways
Protalix BioTherapeutics reported revenues from selling goods of $10.2 million during the three months ended September 30, 2023, an increase of $1.4 million, or 16%, compared to revenues of $8.8 million for the three months ended September 30, 2022. Net loss for the three months ended September 30, 2023 was approximately $1.9 million, or $0.03 per share, basic, and $0.04 per share, diluted, compared to a net loss of $3.6 million, or $0.07 per share, basic and diluted, for the same period in 2022.
Revenues from selling goods increased by $1.4 million, or 16%, compared to the same period last year.
Revenues from license and R&D services decreased by $5.2 million, or 96%, compared to the same period last year.
Cost of goods sold decreased by $2.2 million, or 31%, from the same period last year.
Net loss decreased to $1.9 million, or $0.03 per share, basic, and $0.04 per share, diluted.